IN2012DN03294A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03294A
IN2012DN03294A IN3294DEN2012A IN2012DN03294A IN 2012DN03294 A IN2012DN03294 A IN 2012DN03294A IN 3294DEN2012 A IN3294DEN2012 A IN 3294DEN2012A IN 2012DN03294 A IN2012DN03294 A IN 2012DN03294A
Authority
IN
India
Prior art keywords
epitope
candidate
cross
binding agent
specific binding
Prior art date
Application number
Other languages
English (en)
Inventor
J Chang Gwongjen
D Crill Wayne
Original Assignee
Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And filed Critical Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
Publication of IN2012DN03294A publication Critical patent/IN2012DN03294A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
IN3294DEN2012 2004-07-27 2005-07-27 IN2012DN03294A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59189804P 2004-07-27 2004-07-27
PCT/US2005/026672 WO2006025990A2 (en) 2004-07-27 2005-07-27 Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use

Publications (1)

Publication Number Publication Date
IN2012DN03294A true IN2012DN03294A (enExample) 2015-10-23

Family

ID=36000491

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3294DEN2012 IN2012DN03294A (enExample) 2004-07-27 2005-07-27

Country Status (6)

Country Link
US (3) US7906292B2 (enExample)
EP (1) EP1784487B1 (enExample)
AT (1) ATE521627T1 (enExample)
CA (1) CA2576798C (enExample)
IN (1) IN2012DN03294A (enExample)
WO (1) WO2006025990A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2459709T3 (en) 2009-07-31 2014-12-01 Ge Healthcare Bio Sciences HIGH-REPLACED YELLOW FEBER VIRUS TREASURY WITH INCREASED CELL STORAGE
CA2836501A1 (en) * 2011-07-12 2013-01-17 Gwong-Jen J. Chang Identification of a west nile virus cd4 t cell epitope and use thereof
EP2768847A4 (en) * 2011-10-20 2015-11-11 Us Gov Health & Human Serv DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES WITH MUTATIONS FOR ELIMINATING IMMUNOMINANT CROSS-REACTIVE EPITOPES
WO2014064943A1 (en) * 2012-10-25 2014-05-01 Osaka University Antigenic peptide derived from dengue virus
CN105473603B (zh) 2013-06-26 2019-10-25 北卡罗来纳-查佩尔山大学 用于登革病毒疫苗的方法与组合物
US10060924B2 (en) 2014-03-18 2018-08-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Distinguishing flavivirus infection using a recombinant mutant envelope protein
CN107405392B (zh) * 2015-02-09 2021-05-18 中央研究院 用于增强对抗登革病毒的安全性及免疫力的抗原表位替换的疫苗
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
TW201718638A (zh) 2015-07-21 2017-06-01 現代治療公司 傳染病疫苗
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
WO2017218339A1 (en) * 2016-06-13 2017-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
US10898566B2 (en) 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
WO2018152526A1 (en) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
JP7572780B2 (ja) * 2017-04-26 2024-10-24 エフ． ホフマン－ラ ロシュ アーゲー 可溶性および免疫反応性のジカウイルスｎｓ１ポリペプチド
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
WO2020190750A1 (en) 2019-03-15 2020-09-24 Modernatx, Inc. Hiv rna vaccines
CN111048154B (zh) * 2019-12-10 2023-06-06 上海药明生物技术有限公司 一种抗体表位作图的方法
MX2023004087A (es) * 2020-10-07 2023-09-15 Sanofi Pasteur Pruebas diagnósticas mejoradas.
US12196755B2 (en) 2021-12-02 2025-01-14 Zymeron Corporation Immunoassay platform for the serological discrimination of closely related viruses
US20250188130A1 (en) * 2022-03-17 2025-06-12 The University Of North Carolina At Chapel Hill Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK172110B1 (da) * 1988-04-15 1997-10-27 Gen Hospital Corp Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
ID19548A (id) * 1996-09-24 1998-07-23 Bavarian Nordic Res Inst As Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
BR9910830A (pt) 1998-06-04 2001-02-13 Us Gov Health & Human Serv Vacinas de ácido nucléico para prevenção de infecção flavivìrus
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO2005056600A2 (en) * 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus

Also Published As

Publication number Publication date
US7906292B2 (en) 2011-03-15
CA2576798C (en) 2014-09-09
US20110059131A1 (en) 2011-03-10
CA2576798A1 (en) 2006-03-09
EP1784487A2 (en) 2007-05-16
US20150246951A1 (en) 2015-09-03
US20080248064A1 (en) 2008-10-09
WO2006025990A2 (en) 2006-03-09
ATE521627T1 (de) 2011-09-15
EP1784487B1 (en) 2011-08-24
US9000141B2 (en) 2015-04-07
WO2006025990A3 (en) 2006-06-29
US9650422B2 (en) 2017-05-16

Similar Documents

Publication Publication Date Title
IN2012DN03294A (enExample)
HRP20190220T1 (hr) Anti-il-23 protutijela, pripravci, postupci i upotrebe
NZ581470A (en) Sequence based engineering and optimization of single chain antibodies
MX348414B (es) Poblaciones de celula madre de la placenta.
TW200714294A (en) Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
IL195338A0 (en) Optimized fc variants and methods for their generation
MY163480A (en) Sclerostin binding agents
WO2006105152A3 (en) Amnion-derived cell compositions, methods of making and uses thereof
AR060583A1 (es) Anticuerpo de c- kit humanizado
WO2009149956A3 (en) Fusion protein and use thereof
TW200723252A (en) Information processing device, information recording medium manufacturing device, information recording medium, methods thereof, and computer program
DE602006007032D1 (de) Bitumenzusammensetzung
WO2006137977A3 (en) Device specific content indexing for optimized device operation
AU2019268061A1 (en) Placental stem cell populations
ATE500503T1 (de) Cd86- und cd80-rezeptorkonkurrenztests
UA88308C2 (ru) Агент образования олеогеля, который содержит тритерпен, олеогель и способ его получения
TW200720170A (en) Work transfer system
WO2006134190A3 (es) Agentes y métodos basados en el uso del dominio eda de la fibronectina
WO2007028079A3 (en) Methods of stimulating expansion of hematopoietic stem cells
MX2008009830A (es) Efecto del inhibidor bst2.
WO2005116252A3 (en) Methods for evaluating ribonucleotide sequences
ATE467128T1 (de) Kolloidale metallkonjugate
TW200626128A (en) Materials and methods for improving shellfish health, immunity and growth
IL191782A0 (en) Method for generating dendritic cells employing decreased temperature
EA200970074A1 (ru) Химический способ создания давления